Altris AI Launches Advanced Flagging System to Transform OCT Data Search
Altris AI has introduced a new flagging system designed to help eye care professionals efficiently navigate vast archives of OCT scans, including historical data. This innovation is designed to enable instant identification of retina pathologies and biomarkers across more than 70 conditions, streamlining both clinical and research workflows.
With the new functionality, clinicians can quickly filter and retrieve OCT scans based on specific pathologies or biomarkers. For example, specialists can now instantly locate all scans from patients with soft drusen or dry AMD, allowing them to create well-defined patient cohorts for diagnostic review, follow-up, or research studies.
For those monitoring geographic atrophy (GA), the system also allows exclusion of GA biomarkers within the 1, 3, and 6 mm ETDRS zones. This capability helps clinicians detect the earliest stages of GA development, when intervention may be most impactful.
According to Altris, the flagging system works across large datasets, including OCT scans from different imaging devices, ensuring a high degree of precision and interoperability.
“Flags are a clinical shortcut,” said Maria Znamenska, MD, PhD, Chief Medical Officer at Altris AI. “Instead of manually searching through thousands of scans, you can now filter precisely for what you need—whether that’s subretinal fluid, GA progression, or early glaucoma indicators. It’s about making the data work for you.”
The new flagging feature is designed to empower eye care professionals to:
Track risk-related biomarkers and set reminders for timely patient follow-ups
Identify clinical study candidates within minutes by scanning large historical datasets
Support new treatment adoption by pinpointing patients who match eligibility criteria
Study rare or complex cases by filtering unique pathology and biomarker combinations for deeper clinical insights
“Flags make it possible to build patient cohorts in minutes,” Dr. Znamenska added. “Whether it’s for research or introducing a new therapy, you now have a reliable tool to search for the right patients efficiently. For example, with the FDA’s recent approval of the first treatment for Macular Telangiectasia Type 2, eye care specialists can search their patient database and identify those affected within minutes—ensuring patients benefit quickly from emerging therapies.”